Weekly chemotherapy instead of best supportive care alone must be considered for patients of small cell lung cancer with poor performance status.

被引：0
|
作者：
Shrivastav, Gunjan
Gupta, Alok
Sonthwal, Neha
Singla, Suhas Kirti
Mohindra, Tarun
Chaturvedi, Harit Kumar
Rohatgi, Nitesh
机构：
[1] Max Inst Canc Care, Delhi, India
[2] Medanta Mediclin, Lucknow, Uttar Pradesh, India
[3] Max Super Specialty Hosp, Max Inst Canc Care, New Delhi, India
[4] Max Healthcare, New Delhi, India
[5] Max Oncol Daycare Ctr, Delhi, India
[6] Max Superspecialty Hosp, New Delhi, India
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21102
引用
收藏
页数：2
相关论文
共 50 条
  • [31] COST OF BEST SUPPORTIVE CARE FOR NON-SMALL CELL LUNG CANCER PATIENTS - A GERMAN PERSPECTIVE
    Schmidt, U.
    Lipp, R.
    Drechsler, M.
    VALUE IN HEALTH, 2014, 17 (07) : A629 - A629
  • [32] Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status
    Stinchcombe, TE
    Choi, J
    Schell, MJ
    Mears, A
    Jones, PE
    Nachtsheim, RV
    Socinski, MA
    LUNG CANCER, 2006, 51 (02) : 237 - 243
  • [33] Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer
    O'Brien, Mary E. R.
    Ciuleanu, Tudor-Eliade
    Tsekov, Hristo
    Shparyk, Yaroslav
    Cucevia, Branka
    Juhasz, Gabor
    Thatcher, Nicholas
    Ross, Graham A.
    Dane, Graham C.
    Crofts, Theresa
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) : 5441 - 5447
  • [34] CISPLATIN CYCLOPHOSPHAMIDE MITOMYCIN COMBINATION CHEMOTHERAPY WITH SUPPORTIVE CARE VERSUS SUPPORTIVE CARE ALONE FOR TREATMENT OF METASTATIC NON-SMALL-CELL LUNG-CANCER
    CARTEI, G
    CARTEI, F
    CANTONE, A
    CAUSARANO, D
    GENCO, G
    TOBALDIN, A
    INTERLANDI, G
    GIRALDI, T
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (10): : 794 - 800
  • [35] Management of patients with non-small cell lung cancer and poor performance status
    Ramaswamy Govindan
    Current Treatment Options in Oncology, 2003, 4 (1) : 55 - 59
  • [36] Topotecan in the treatment of relapsed small cell lung cancer patients with poor performance status
    Treat, J
    Huang, CH
    Lane, SR
    Levin, J
    ONCOLOGIST, 2004, 9 (02): : 173 - 181
  • [37] The Best Supportive Care in Stage III Non-Small-Cell Lung Cancer
    de Oliveira, Thiago Bueno
    Fontes, Debora Maloni Nasti
    Montella, Tatiane Caldas
    Lewgoy, Jairo
    Dutra, Carolina
    Miola, Thais Manfrinato
    CURRENT ONCOLOGY, 2024, 31 (01) : 183 - 202
  • [38] Prognostic factor of patients with advanced non-small cell lung cancer receiving best supportive care
    Kishikawa, Takayuki
    Masuda, Shingo
    Oda, Shinya
    Yamaguchi, Keisuke
    Furusato, Yuichiro
    Furusato, Ayaka
    Yamaguchi, Shota
    Inoue, Shigehiro
    Yasaka, Takahiro
    ANNALS OF ONCOLOGY, 2017, 28
  • [39] RETROSPECTIVE ANALYSIS OF THE CHEMOTHERAPY FOR PATIENTS OF EXTENSIVE SMALL CELL LUNG CANCER WITH POOR PERFORMANCE STATES
    Yomota, M.
    Sekihara, K.
    Nakahara, Y.
    Ookuma, Y.
    Takagi, Y.
    Hosomi, Y.
    Iguchi, M.
    Okamura, T.
    Shibuya, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 104 - 105
  • [40] Survival among non-small cell lung cancer patients with poor performance status after first line chemotherapy
    Salloum, Ramzi G.
    Smith, Thomas J.
    Jensen, Gail A.
    Lafata, Jennifer Elston
    LUNG CANCER, 2012, 77 (03) : 545 - 549
12345